ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course...
Transcript of ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course...
![Page 1: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/1.jpg)
ASTRO Refresher Course – Adult CNS TumorsSpring 2016
Scott G. Soltys, M.D.
Department of Radiation Oncology
Stanford Cancer Institute - Stanford University
La Jolla, CA
March 2016
![Page 2: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/2.jpg)
Disclosure
• Nektar Therapeutics – Consultant
• Stanford University – Employer
![Page 3: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/3.jpg)
Learning Objectives
• Describe the current clinical data underlying the treatment of benign and malignant adult CNS tumors
• Review the data-based recommendations for chemotherapy, surgery and radiotherapy for these tumors
• Understand the evolving molecular tests in CNS tumors which will guide treatment recommendations
• Discuss the benefits and side effects of the multiple treatment options for brain metastases
![Page 4: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/4.jpg)
Goals
• Highlight the data that forms the background of our treatment
• Highlight nuances of clinical treatment and practice
![Page 5: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/5.jpg)
Outline
• High Grade Gliomas
• Low Grade Gliomas
• Brain Metastases
![Page 6: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/6.jpg)
Glioma Histology
• A
• M
• E
• N
![Page 7: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/7.jpg)
Glioma Histology
• Atypia
• Mitotic Figures
• Endothelial Proliferation
• Necrosis
![Page 8: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/8.jpg)
New Era: Molecular Type More Prognostic than Histologic Type
![Page 9: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/9.jpg)
GBM Histology
![Page 10: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/10.jpg)
Gliomas Survival*
• Grade / Type MS (y)
• II Oligo 10
• II Astro 5
• III Oligo 5
• III Astro 3
• IV GBM 1.5
* A gross, but useful, oversimplification
![Page 11: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/11.jpg)
Gliomas Survival*
• Grade / Type MS (y)
• II Oligo 10
• II Astro 5
• III Oligo del 1p/19q 10
• III Oligo intact 1p/19q 3
• III Astro 3
• IV GBM 1.5
* A gross, but useful, oversimplification
![Page 12: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/12.jpg)
GBM Treatments
• Surgery
• Radiation
• Chemotherapy
![Page 13: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/13.jpg)
GBM – Extent of Resection
![Page 14: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/14.jpg)
HGG: Role for Radiotherapy• BTSG 69-01
n=303 patients, high grade gliomas
Median OS (months)
• BCNU alone 4.2
• RT alone (50-60 Gy WBRT) 8.1
• RT + BCNU 8.0
• Supportive Care 3.2
First data for for post-operative RT over supportive management
…and the only positive trial (other than BCNU wafers) for GBM until Stupp
Walker, JNS, 49, 1978
![Page 15: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/15.jpg)
Audience Question 1 In recent randomized trials, the overall median survival for good performance status patients with GBM (Glioblastoma Multiforme) is closest to:
1. 12 Months
2. 14 Months
3. 17 Months
4. 24 Months
![Page 16: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/16.jpg)
Audience Question 1 - Answer In recent randomized trials, the overall median survival for good performance status patients with GBM (Glioblastoma Multiforme) is closest to:
1. 12 Months
2. 14 Months
3. 17 Months
4. 24 Months
Stupp: 12.1 (RT) 14.6 (RT+TMZ) months
RTOG 0825: 16 months
AVAglio: 17 months
![Page 17: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/17.jpg)
Current Standard of Care:EORTC 26981-22981/NCIC CE.3
• n=573 GBM
• Age 18-70y WHO 0-2
• RT 60Gy
• RT 60Gy + TMZ TMZ
• Temozolomide (TMZ)– 75mg/m2 QD during RT
– 150-200mg/m2 d1-5 q28d x 6
– PCP prophylaxisStupp, NEJM 352, 2005
![Page 18: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/18.jpg)
Stupp 5 Year Update
Median OS: 12.1 vs. 14.6 months
2y OS: 11 vs. 27 %
Stupp Lancet 10, 2009
![Page 19: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/19.jpg)
Hyper-Methylated MGMT
Median OS: 23.4 vs. 15.3
No Hyper-Methylated MGMT
Median OS: 12.6 vs. 11.8
Stupp 5 Year Update
Stupp Lancet 10, 2009
![Page 20: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/20.jpg)
Newly Diagnosed GBM: Role of Bevacizmab
Citation: Arms Median OS (months)
RTOG 0825Gilbert NEJM 370, 2014
60 Gy + TMZ TMZ 16.1
60 Gy + TMZ TMZ + BEV 15.7
AVAglioChinot NEJM 370, 2014
60 Gy + TMZ TMZ 16.7
60 Gy + TMZ TMZ + BEV 16.8
Bevacizumab does not improve OS for newly diagnosed GBM
First trial to prospectively show MGMT status as prognostic
![Page 21: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/21.jpg)
Radiotherapy Fields
![Page 22: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/22.jpg)
RTOG RT Fields
• Initial to 46Gy:
– T2 Edema + 2-3 cm
• Boost to 60Gy:
– T1 post-Gad enhancement + 2-3 cm
![Page 23: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/23.jpg)
EORTC/NCIC RT Fields
• Initial to 46Gy:
– T2 Edema + 2-3 cm
• Treat to 60Gy (no cone down):
– T1 post-Gad enhancement + 2-3 cm
• Current EORTC trial:
– T1 post-contrast + 1.5 cm CTV + 0.5 cm PTV
![Page 24: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/24.jpg)
ESTRO Contouring Guidelines
Niyazi Rad Onc 118, 2016
![Page 25: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/25.jpg)
Audience Question 2 In planning radiotherapy volumes for GBM, I typically use:
1. 46 Gy to Edema + 14 Gy Cone Down = 60 Gy (RTOG)
2. 60 Gy to Cavity/Tumor (No Edema) = 60 Gy (EORTC)
3. Different Volume to 60 Gy
4. Different Dose other than 60 Gy
5. None of the above
![Page 26: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/26.jpg)
Audience Question 2 - AnswerIn planning radiotherapy volumes for GBM, I typically use:
Standard of Care:
Dose – 60 Gy
Volume – no standard
![Page 27: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/27.jpg)
Justification for EORTC fields (no edema):
• Retrospective studies:
– Larger volume of brain treated, but no difference in patterns of failure with smaller field
• Minniti Rad Onc, 2010
• Chang IJROBP 68, 2007
• Prospective data (but not the primary endpoint)
–RTOG 05251 and CENTRIC2:
No difference in OS between EORTC and RTOG sites
1. Gilbert JCO 31, 2013 2. Stupp Lancet Onc 15, 2014
![Page 28: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/28.jpg)
ESTRO Contouring Guidelines
Niyazi Rad Onc 118, 2016
![Page 29: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/29.jpg)
XRT Fields
• Notes:
–CTV is an anatomic concept, therefore can decrease CTV margin in areas where glioma cannot go
• e.g., shave at tentorium, bone, falx (but not at falx around corpus callosum)
–PTV is a geometric concept and is based on your machine, image fusion, intra- and inter-fraction movement, etc. Therefore no shaving of PTV
![Page 30: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/30.jpg)
Contouring Example
Niyazi Rad Onc 118, 2016
![Page 31: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/31.jpg)
Radiotherapy Dose
![Page 32: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/32.jpg)
BTSG - Dose Responseretrospective from 66-01, 69-01, 72-01
Walker IJROBP 5, 1979
Dose (WBRT) Median OS (wks) 0 18
50 2855 3660 42
![Page 33: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/33.jpg)
RTOG 93-05: ChemoRT +/- SRS Boost
• n=203 GBM (<40cc)
Median OS
• 60Gy + BCNU 13.6
• 60Gy + BCNU + upfront SRS 13.5
– SRS per RTOG 90-05
• 0-2cm 24Gy, 2-3cm 18Gy, 3-4cm 15Gy
• No benefit to SRS in newly diagnosed GBM
Souhami IJROBP 60, 2004
![Page 34: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/34.jpg)
NRG-BN001
![Page 35: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/35.jpg)
Post-ChemoRT Follow-up
• MRI at 1 month, then every 2 months
![Page 36: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/36.jpg)
• 1st MRI:
–½ bigger
–of those bigger – 2/3 are psPD
– If psPD: 2/3 Me’d MGMT
– If ePD: 90% un-Me MGMT
Brandes JCO 26, 2008
Post-ChemoRT(Pseudo)-Progression
![Page 37: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/37.jpg)
MGMT Methylated: More Pseudoprogression
Brandes JCO 26, 2008
![Page 38: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/38.jpg)
Pseudo-progression
1 month 3 months 5 monthsPrior to RT/TMZ
![Page 39: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/39.jpg)
MGMT and Patterns of Failure
• n=95– MGMT me’d – 34%
• Failure outside of field*– MGMT un-me’d: 15%
– MGMT me’d: 40%
• Time to Progression:– In-field 9m
– Out of field 15m
• *Historically – only ~15% distant failures Brandes JCO 27, 2009
![Page 40: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/40.jpg)
Response Assessment in Neuro-Oncology (RANO) Criteria
• Progression <3 months post-Tx ONLY if:
– New enhancement beyond 80% Isodose line
– Unequivocal pathologic evidence of viable tumor
Wen JCO 28, 2010
![Page 41: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/41.jpg)
GBM in those with advanced age or lower KPS
![Page 42: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/42.jpg)
GBM in the ‘Elderly’Citation Arms Median OS
(months)Conclusion
Keime-GuibertNEJM 356, 2007
No RT 4.3 RT better than nothing
50.4 Gy 7.3
Roa JCO 22, 2004 60 Gy in 30 frx 5.1 Short course no different than long course
40 Gy in 15 frx 5.6
Wick NOA-08Lancet 2012
60 Gy in 30 frx 9.6 TMZ is non-inferior to 60 Gy RTEFS for MGMT Me’d: TMZ better (8.4 vs. 4.6)EFS for MGMT not Me’d: RT better (4.6 vs. 3.3)
TMZ 7 days in 14 8.6
MalmstromLancet 2012
60 Gy in 30 Frx 6.0 60 Gy in 30 worse than 34 Gy in 1034 Gy in 10 not different than TMZ34 Gy in 10 Frx 7.5
TMZ 5 days in 28 8.3
Roa IAEA JCO 33, 2015
40 Gy in 15 frx 6.4 25 Gy in 5 non-inferior to 40 Gy in 15
25 Gy in 5 frx 7.9
![Page 43: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/43.jpg)
EORTC 26062-22061 / NCIC CE.6
• Activated: 08/2009 Accrual Met 10/2013
• n=560
• Stratified by:– Center, KPS, Resection extent
– Age (65-70, 71-75, >75 yo)
• Exclusion: Candidates for 60Gy + TMZ
• RT 40Gy (2.67Gy x 15) + TMZ TMZ
• RT 40Gy (2.67Gy x 15)
![Page 44: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/44.jpg)
‘Elderly’ GBM Treatment SchemaKPS Treatment_____________________________
High TMZ + RT 60 Gy in 30 (Stupp)
Normal TMZ + RT 40 Gy in 15 (Minniti IJROBP 83, 2012)
Mid TMZ or RT single agent
TMZ alone: if MGMT Me’d (Wick)
RT alone: if MGMT not Me’d (Wick)
RT Options: 34 Gy in 10 (Malmstrom)
40 Gy in 15 (Roa)
25 Gy in 5 (Roa)
Bevacizumab alone
Low Supportive Care
![Page 45: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/45.jpg)
Recurrent GBM
![Page 46: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/46.jpg)
GBM Re-Irradiation
• n=147
• Median 35 Gy in 10 fractions to T1 post-contrast GTV
• Median OS – 11 m
Fogh JCO 28, 2010
![Page 47: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/47.jpg)
RTOG 1205
![Page 48: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/48.jpg)
Recurrent GBM – Tumor Treating Fields (TTF)
• n=237 rGBM
• NovoTTF
• Best chemo
Stupp EuroJ Cancer 48, 2012
![Page 49: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/49.jpg)
Newly Diagnosed GBM: Tumor Treating Fields (TTF)
• n=695
Median OS
• 60 Gy + TMZ TMZ 15.6
• 60 Gy + TMZ TMZ + TTF 20.5
TTF >18 hours per day
Stupp JAMA 314, 2015
![Page 50: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/50.jpg)
Outline
• High Grade Gliomas - Oligos
• Low Grade Gliomas
• Brain Metastases
![Page 51: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/51.jpg)
Anaplastic Oligodendrogliomas - 2006Citation Arms Median PFS (Years) Median OS (Years) Notes:
RTOG 9402Cairncross JCO 24, 2006
59.4 Gy 1.7 4.7 PCV does not improve OS
PCV does improve PFS for 1p19q codeleted
iPCV x 4 59.4 Gy 2.6 (sig) 4.9
EORTC 26951van den Bent JCO 24, 2006
59.4 Gy 1.1 2.5
59.4 Gy PCV x 6 1.9 (sig) 3.4 (NS)
![Page 52: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/52.jpg)
Anaplastic Oligodendrogliomas - 2012Citation Arms Median OS (Years)
1p19q CODELMedian OS (Years) 1p19q non-CODEL
Notes:
RTOG 9402Cairncross JCO 30, 2012
59.4 Gy 7.3 2.7 New Standard of Care.
Sequential ChemoRT has no role in non-codeleted
iPCV x 4 59.4 Gy 14.7 2.6
EORTC 26951van den Bent JCO 30, 2012
59.4 Gy 9.3 1.8
59.4 Gy PCV x 6 Not Reached 2.1
• Although an unplanned analysis (1p19q unknown in 1994), standard of care is sequential RTchemo if if 1p19q codeleted
• Role of TMZ vs. PCV is unknown
![Page 53: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/53.jpg)
If not codeleted Anaplastic Oligodendroglioma
Cairncross JCO 30, 2012
No benefit to adding chemo in all non-codeleted patients.
But appears to be a benefit in some….
![Page 54: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/54.jpg)
PCV improves OS for non-codeleted, but IDH Mutated Anaplastic Oligos
Cairncross JCO 32, 2014
Arms Median OS (Years) Codeleted
IDH1 Mutant
Median OS (Years) non-codeletedIDH1 Mutant
Median OS (Years)non-codeleted
IDH1 wt
59.4 Gy 6.8 3.3 1.8
iPCV x 4 59.4 Gy 14.7 5.5 (sig) 1.3 (NS)
![Page 55: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/55.jpg)
Standard of Care – Anaplastic Oligos
• Sequential RT Chemo or Chemo RT if:– 1p19q codeleted
• MS 14.7 vs. 7.3 years
– 1p19q non-codeleted, but IDH1 mutated• MS 5.5 v 3.3 years
• No standard of care for non-codeleted:• These are really molecular astrocytomas (not oligos)• We know no benefit from sequential chemo
– unknown if would benefit from Stupp concurrent chemo?
![Page 56: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/56.jpg)
Anaplastic Astrocytoma
• May extrapolate from Stupp and do concurrent RT + TMZ (no data for this)
• But best data-based answers are:
• Sequential RT PCV is no benefit over RT alone
• The non-codeleted 9402 Oligos are molecular astros
– Single agent RT or single agent chemo, as per NOA-04…
![Page 57: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/57.jpg)
NOA-04 Grade III Trial
• n=318 AA/AO 1999-2005
• 59.6-60 Gy to GTV+2cm
• Primary Endpoint: TTF
Wick JCO 27, 2009
![Page 58: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/58.jpg)
NOA-04 Grade III Trial
• No difference with chemo 1st or RT 1st
• AA vs. AO or AOA
• MGMT me’d predictive and prognostic for RT alone
• No difference in PCV vs. TMZ
Wick JCO 27, 2009
![Page 59: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/59.jpg)
Outline
• High Grade Gliomas
• Low Grade Gliomas
• Brain Metastases
![Page 60: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/60.jpg)
Audience Question 3 When treating a RTOG high risk (age > 40 or subtotallyresected) low grade glioma, the standard of care is:
1. Radiotherapy alone
2. Chemotherapy alone, then RT at time of progression
3. Sequential radiotherapy then chemotherapy
4. Concurrent chemoradiotherapy adjuvant chemo
![Page 61: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/61.jpg)
Audience Question 3 - Answer When treating a RTOG high risk (age > 40 or subtotallyresected) low grade glioma, the standard of care is:
1. Radiotherapy alone - ‘Believers’
2. Chemotherapy alone, then RT at time of progression - ‘Non-Believers’
3. Sequential radiotherapy then chemotherapy - RTOG 9802
4. Concurrent chemoradiotherapy adjuvant chemo - Stupp/RTOG 0424
Note: Role of Temozolomide vs. PCV unknown
RTOG 0424 was single arm (hypothesis-generating) trial
![Page 62: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/62.jpg)
LGG: Summary• Old Answer:
– Radiotherapy: • Overall – does not increase OS (Non-Believers)
• Overall – does increase PFS (Non-Believers)
– Main debate was on whether progression of tumor or the effect of RT was worse
• New Answer:
– RTOG High risk (>40 or STR) - RTOG 9802• Sequential 54 Gy PCV better than 54 alone
• New Standard of Care if treated
• Doesn’t define when to treat
– Role of TMZ vs. PCV unknown:• EORTC High risk (3 of 5 Pignatti) – RTOG 0424
– Concurrent 54 Gy + Stupp chemo better than historic 54 Gy alone
– Hypothesis generating single arm trial
![Page 63: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/63.jpg)
Olar Sem Rad Onc 25, 2015
Entering into a New Era: Molecular Type Trumps Histologic Type
![Page 64: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/64.jpg)
LGG: Extent of Resection
![Page 65: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/65.jpg)
LGG Radiotherapy – Timing and Dose
• What is the best timing:
– EORTC 22845 - ‘Non-Believers’
• What is the best dose
– EORTC 22844 - ‘Believers’
–NCCTG/RTOG/ECOG
![Page 66: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/66.jpg)
‘Non-Believers’ – EORTC
• n=290
–60% Astro, 25% Oligo, 10% MOA
• 0 Gy
• 54 Gy
• CTV+2 to 45 Gy, CTV+1 to 54 Gy
• Really is an upfront RT vs. RT at recurrence trial
Karim IJROBP 52, 2002
![Page 67: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/67.jpg)
‘Non-Believers’ Update – PFS and OS
van den Bent Lancet 366, 2005
![Page 68: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/68.jpg)
‘Non-Believers’ Update
• Therefore upfront RT improves PFS, but not OS
• Does improve seizures- Seizures at 1 year:
No XRT 41%
XRT 25%
• Does not increase the risk of transformation to GBM at time of recurrence:
No XRT 66%
XRT 72%
van den Bent Lancet 366, 2005
![Page 69: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/69.jpg)
‘Believers’ – EORTC
• n=379
• Randomized after surgery:– 60% Astro, 22% Oligo, 10% MOA
• 45 Gy
• 59.4 Gy
• CTV+2 to 45 Gy, CTV+1 to 54 Gy, CTV+0 to 59.4 Gy
Karim IJROBP 36, 1996
![Page 70: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/70.jpg)
‘Believers’ – EORTC
Karim IJROBP 36, 1996
• Conclusion: No dose response at 45 v 59.4 Gy
![Page 71: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/71.jpg)
NCCTG/RTOG/ECOG
• n=203
–95% LGG, 5% Grade I
• 50.4 Gy
• 64.8 Gy
• CTV+2 to 50.4, CTV+1 to 64.8
Shaw JCO 20, 2002
![Page 72: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/72.jpg)
Shaw JCO 20, 2002
NCCTG/RTOG/ECOG – OS and Toxicity
![Page 73: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/73.jpg)
LGG: Dose and Volumes
• Current trials (EORTC, RTOG) use 50.4 – 54 Gy
• RTOG 1072:
–50.4 Gy in 1.8Gy
–GTV = resection cavity + any T2/FLAIR
–CTV = GTV + 1cm (not extending outside brain)
–PTV = CTV + 0.5cm
![Page 74: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/74.jpg)
LGG: Risk Stratification
• EORTC High Risk is 3-5 High Risk Features:1. Age > 40 yo2. Diameter > 6 cm3. Tumor crosses midline4. Astrocytoma (not oligo)5. Neurologic Symptoms prior to surgery
– Median OS: • 0-2 features 7.7 years• 3-5 features 3.2 years
Pignatti JCO 20, 2002
![Page 75: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/75.jpg)
RTOG 0424 – High Risk LGG with RT/TMZ
• n=129 LGG with 3-5 EORTC/Pignatti risk factors
• Single arm: 54 Gy + TMZ TMZ (Stupp chemo)
• Designed to detect a 43% increase in MS from 40.5 to 57.9 months and a 20% improvement in 3-year overall survival (OS) rate from 54% to 65% at a 10% significance level (1-sided) and 96% power.
• Results at 4.1 year median F/U:– MS not reached
– 3y OS 73%
– Hypothesis Generating Trial
Fisher IJROBP 91, 2015
![Page 76: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/76.jpg)
RTOG 9802: RT vs. RT PCV for High Risk LGG
Shaw JCO 30, 2012
Citation Arms Median PFS (Years)
Median OS (Years)
Shaw JCO 30, 2012
54 Gy 4.4 7.5
54 Gy PCV x 6 Not reached Not reached
Not PublishedASCO 2014
van den Bent Neuro-Onc16, 2014
54 Gy 4.0 7.8
54 Gy PCV x 6 10.4 13.3
High Risk: Age > 40 or Sub-total resection
![Page 77: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/77.jpg)
RTOG 9802: New standard of care
• High risk LGG pts (RTOG High risk):
– RT alone is inferior
• await molecular subtype analysis – likely more benefit to PCV for oligos
– Sequential RT chemo better OS than RT alone
• MS 7.8 vs. 13.3 years for LGG
• Note: very similar to RTOG 9402 Codeleted Oligo (7.3 vs. 14.7 years)
• This tells you how to treat, but not when to treat
![Page 78: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/78.jpg)
Outline
• High Grade Gliomas
• Low Grade Gliomas
• Brain Metastases
![Page 79: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/79.jpg)
Audience Question 4 For brain metastases treated with radiosurgery alone, omitting whole brain irradiation, the rate of new brain metastases appearing in 1 year is approximately:
1. 0–20%
2. 40-60%
3. 60-80%
4. 80-100%
![Page 80: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/80.jpg)
Audience Question 4 - AnswerFor brain metastases treated with radiosurgery alone, omitting whole brain irradiation, the rate of new brain metastases appearing in 1 year is approximately:
1. 0–20%
2. 40-60%
3. 60-80%
4. 80-100%
Most all prospective and retrospective data show approximately 50% chance in 1 year of new brain metastases with the omission of WBRT.
![Page 81: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/81.jpg)
Brain Metastases – Key Points
• Post-op RT is needed following a gross total resection
– Local Failure 55-65% with GTR alone
• WBRT – no data to show that it improves OS (but no trial powered)
Improves rate of new brain metastases
If SRS alone ~50% new met in 1 year
Improves neurologic death rate (in 2 of 3 trials)
14-28% with WBRT; 44% without WBRT
• Local intensification (Surgery or SRS) does improve OS if added to WBRT
But only in good KPS patients or single metastasis
• WBRT – leads to cognitive dysfunction
• Intracranial progression – leads to cognitive dysfunction
![Page 82: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/82.jpg)
Decadron Dose – Randomized Trial
• n=96, brain met, KPS<80
• Dose (Total QD) Improved KPS (points)
• 16mg 7.3 (1w)
• 8mg 8.0 (1w)
• 16mg 9.1 (1w) 5.6(4w)
• 4mg 6.7 (1w) 7.1(4w)
• 16mg more toxic (p<.03)
• Therefore, if high dose needed, then 8mg BID x 1 week, but can usually quickly drop to 2mg BID in most patients
Vecht Neurology 44, 1994
![Page 83: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/83.jpg)
Brain Metastases - RPA
• Brain Met RPA
– Class I: <65yo
KPS>70
Controlled Primary
No extracranial mets
– Class II: Not I or III
– Class III: KPS<70
– n=1200
MS
7.1 m
4.2 m
2.3 m
Incidence
20%
65%
15%
Gaspar IJROBP 37, 1997
![Page 84: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/84.jpg)
GPA: Graded Prognostic Assessment
• developed from n=1960 RTOG patients
Sperduto IJROBP 70, 2008
More objective that RPA, as don’t need to know systemic disease status
![Page 85: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/85.jpg)
Disease Specific GPA
Sperduto JCO 30, 2012
![Page 86: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/86.jpg)
Disease Specific GPA
Sperduto JCO 30, 2012
![Page 87: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/87.jpg)
Controversy: Size vs. Number?
Which is worse for survival?
10 mets x 1 cm 2 mets x 2cm
![Page 88: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/88.jpg)
Controversy: Size vs. Number?
Which is worse for survival?
10 mets x 1 cm = 5 cc 2 mets x 2cm = 8.4 cc
![Page 89: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/89.jpg)
Volume is More Important that Number
Citation Multivariate Analysis for Overall Survival
Volume of Metastases
Number of Metastases
BhatnagarIJROBP 2006
p = 0.002 p = 0.3 (NS)
LikhachevaIJROBP 2012
p <0.001 p = 0.2 (NS)
BaschnagelJNS 2013
p = 0.003 p = 0.1 (NS)
ChoiIJROBP 2012
p = 0.01 p = NS
![Page 90: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/90.jpg)
Yamamoto Lancet Onc 15, 2014
• n=1194
• 1-10 metastases treated with SRS alone
• Survival non-inferior for 5-10 vs. 2-4 metastases
• Leptomeningeal Disease 13%
• WBRT 9%
SRS for 1 – 10 Metastases: Prospective
![Page 91: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/91.jpg)
Brain Metastases – Treatment Options
• Surgery
• WBRT
• WBRT + Surgery
• WBRT + SRS
• SRS
• Surgery SRS
![Page 92: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/92.jpg)
Brain Metastases – Treatment Options
• Surgery
• WBRT
• WBRT + Surgery
• WBRT + SRS
• SRS
• Surgery SRS
Question: Is surgery alone (without WBRT)adequate treatment?
![Page 93: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/93.jpg)
Brain Metastases: Surgery +/- WBRT
• n=95
– Single met, KPS>70, GTR by MRI
• Surgery
• Surgery + WBRT (50.4 Gy in 1.8)
Patchell JAMA 17:280, 1998
![Page 94: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/94.jpg)
Brain Metastases: Surgery +/- WBRT
• n=95
• Surgery
• Surgery + WBRT
• Primary endpoint: LC (not survival)
Crude Incidence of Recurrence
Median OS
All Brain Local Control
Distant Control
11 m 70 46 37
12 m 18 10 14
Patchell JAMA 17:280, 1998
![Page 95: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/95.jpg)
Brain Metastases: Surgery +/- WBRT
• n=95
• Surgery
• Surgery + WBRT
Crude Incidence of Recurrence
Median OS
All Brain Local Control
Distant Control
11 m 70 46 37
12 m 18 10 14
Patchell JAMA 17:280, 1998
• But, the above are crude incidences.
• The actual curves show:
1yr rate Surg LF 63% DF 50%
Surg+WBRT LF 14% DF 18%
![Page 96: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/96.jpg)
1 yr Local Failure:
Surgery ~66%
Surgery + WBRT ~20%
Patchell JAMA 17:280, 1998
Surgery
Surgery + WBRT
Brain Metastases: Surgery +/- WBRT
![Page 97: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/97.jpg)
Brain Metastases: Surgery +/- WBRT
1 yr Distant Failure:
Surgery ~50%
Surgery + WBRT ~18%
Patchell JAMA 17:280, 1998
Surgery
Surgery + WBRT
![Page 98: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/98.jpg)
Brain Metastases: Surgery +/- WBRT
• n=95 Death
Neurologic Systemic
• Surgery 44% 46%
• Surgery+WBRT 14% 84%
• No difference in Functionally Independent Survival or OS
Patchell JAMA 17:280, 1998
![Page 99: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/99.jpg)
EORTC 22952-26001
• n=359
• 1-3 Metastases
• Stable systemic disease
• WHO PS 0-2
Kocher JCO 29, 2011
![Page 100: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/100.jpg)
EORTC 22952-26001
• SRS
• SRS + WBRT (30Gy)
• Surgery
• Surgery + WBRT (30Gy)
SRS: GTV + 1-2mm to 20Gy
3.5cm max or 2.5cm if multiple
Surgery: GTR required (surgeon or MRI)
~Aoyama
~Patchell
Kocher JCO 29, 2011
![Page 101: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/101.jpg)
EORTC 22952-26001
• SRS
• SRS + WBRT (30Gy)
• Surgery
• Surgery + WBRT (30Gy)
Primary Outcome:
Duration of Functional Independence (Time to WHO PS>2)
~Aoyama
~Patchell
Kocher JCO 29, 2011
![Page 102: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/102.jpg)
EORTC 22952-26001FIS Median: No WBRT 9.5m
WBRT 10.0m
OS Median: No WBRT 10.9m
WBRT 10.7m
Neurologic death:
No WBRT 44%
WBRT 28%
Kocher JCO 29, 2011
![Page 103: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/103.jpg)
24 Month failure: Local Distant
• Surgery 59 42
• Surgery+WBRT 27 23
• SRS 31 48
• SRS + WBRT 19 33
Kocher JCO 29, 2011
![Page 104: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/104.jpg)
EORTC 22952-26001 Conclusion
Kocher JCO 29, 2011
• WBRT does not improve:
– functionally independent survival
–overall survival
• WBRT does improve:
– Local Control
–Distant intracranial control
–Neurologic death rate
![Page 105: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/105.jpg)
Brain Metastases: RT is needed after a GTR
Citation 1 yr Local Failure *
Surgery alone Surgery + WBRT
Patchell JAMA 1998
66 20
Kocher JCO 2010
55 27
* Rates Approximated from Survival Curves
![Page 106: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/106.jpg)
Brain Metastases – Treatment Options
• Surgery
• WBRT
• WBRT + Surgery
• WBRT + SRS
• SRS
• Surgery SRS
Question: How does intensification of local treatment with surgery help?
![Page 107: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/107.jpg)
Brain Metastases: WBRT +/- SurgeryCitation Outcome WBRT WBRT +
SurgeryNotes
Patchell NEJM 322, 1990
Local Failure % 52 20
Median OS (months) 4 10
Vecht Ann Neuro 33, 1993
Median OS (months) 6 10
Median OS (months) Controlled systemically
7 12
Median OS (months) Uncontrolled systemically
5 5
Mintz Cancer 78, 1996
Median OS (months) 6 6 Worse KPS and extracranialmets
![Page 108: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/108.jpg)
WBRT Fields
![Page 109: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/109.jpg)
Brain Metastases – Treatment Options
• Surgery
• WBRT
• WBRT + Surgery
• WBRT + SRS
• SRS
• Surgery SRS
Question: How does intensification of local treatment with SRS help?
![Page 110: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/110.jpg)
Brain Metastases: WBRT +/- SRS #2
• RTOG 9508
• n=333 1-3 metastases KPS >70
• WBRT 37.5 in 2.5
• WBRT + SRS– 1 wk after WBRT. SRS dose: 24Gy, 18Gy, 15Gy per RTOG 9005
• Primary endpoint: Survival
– Secondary: Tumor LC, Brain LC, KPS
Andrews Lancet 363, 2004
![Page 111: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/111.jpg)
SRS Dosing: RTOG 9005
• n=156
• Dose escalation trial to find Maximum Tolerated Dose (MTD) of SRS
• Recurrent metastases or primary brain tumors
– i.e., ALL had prior RT (~60 Gy or 30 Gy) a median 17 months prior to SRS*
• *A common question is if we need to alter our WBRT dose/plan to account for past SRS No, as our SRS dose is based on those that got WBRT
Shaw IJROBP 47: 291, 2000
![Page 112: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/112.jpg)
SRS Dosing: RTOG 9005 Results
FINAL Recommendations:
<2 cm: 24Gy
2.1-3.0 cm: 18Gy
3.1-4.0 cm: 15Gy
Shaw IJROBP 47: 291, 2000
![Page 113: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/113.jpg)
Andrews Lancet 363, 2004
![Page 114: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/114.jpg)
Brain Metastases: WBRT +/- SRS #2
Conclusion:
SRS improves overall survival for those with a single metastasis
Andrews Lancet 363, 2004
![Page 115: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/115.jpg)
Brain Metastases – Treatment Options
• Surgery
• WBRT
• WBRT + Surgery
• WBRT + SRS
• SRS
• Surgery SRS
Question: What does WBRT add to SRS?
![Page 116: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/116.jpg)
Brain Metastases: SRS +/- WBRT
Citation SRS SRS + WBRT
AoyamaJAMA 295, 2006
Median OS (Months) 8 8
Local Control (1 year) 73 89
Distant Control (1 year) 64 42
Neurologic Death 19 23
ChangLancet Onc 2009
Cognitive Decline (HVLT at 4 months)
24 52
Median OS (months) 15 6
Distant Control (1 year) 45 73
![Page 117: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/117.jpg)
NCCTG N0574: SRS vs. SRS + WBRT
• n=213
• 1-3 metastases, each <3cm
• Endpoint: Cognitive Progression at 3 months – (>1 SD in any of 6 cognitive tests)
CogProg mOS 1y Brain Control
• SRS 62 10.7 51
• SRS + WBRT 88 7.5 85p=0.002 p=0.93 p<0.001
Brown ASCO Plenary 2015
![Page 118: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/118.jpg)
Brain Metastases – Treatment Options
• Surgery
• WBRT
• WBRT + Surgery
• WBRT + SRS
• SRS
• Surgery SRS
Question: Can we do SRS to resection cavity rather than WBRT following surgery?
![Page 119: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/119.jpg)
Pending Prospective Data: RTOG 1270/NCCTG N107C
![Page 120: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/120.jpg)
Brain Metastases – Treatment Options
• Question: Are there ways to improve the cognitive outcomes of WBRT?
• Memantine
• Hippocampal Avoidance WBRT
![Page 121: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/121.jpg)
RTOG 0614 WBRT + Memantine
• n=508 evaluable
• WBRT (37.5 Gy) + placebo
• WBRT (37.5 Gy) + Memantine x 6 months
• Primary: HVLT-R DR at 6 months• Tests:
– Memory (Hopkins Verbal Learning Test-Revised [HVLT-R])
– Processing speed (Trail Making Test Part A [TMT-A])
– Executive function (Trail Making Test Part B [TMT-B])
– Verbal fluency (Controlled Oral Word Association [COWA])
– MMSE
• Titrate dose up q1w x 4 weeks:
– 5 am 5 BID 10 am 5 pm 10 BID
– Sig: Memantine Titration pack, then 10 BID x 5 months
Brown Neuro-Onc 15, 2013
![Page 122: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/122.jpg)
RTOG 0614 WBRT + Memantine
• OS: 7 v 8 m (p=0.28)
• Only 149 analyzable pts (29%) at 6 months
–442 (80%) expected
• HVLT-R DR better with Memantine, but p=0.059
Brown Neuro-Onc 15, 2013
![Page 123: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/123.jpg)
RTOG 0614 WBRT + Memantine
Cognitive Function Failure = Failure in any of the tests
Brown Neuro-Onc 15, 2013
![Page 124: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/124.jpg)
RTOG 0933: Hippocampal Avoidance WBRT (HA-WBRT)
• Single arm phase II• n=113 with HA-WBRT (30 Gy in 10)
– Hippo+5mm: 100% < 9 Gy, Dmax <16 Gy
• Primary endpoint: Mean Relative Decline in HVLT-DR at 4 months compared to baseline– Compared to WBRT alone (Li JCO 25, 2007)
• HA-WBRT: 7% decline• WBRT: 30% decline
Gondi JCO 32, 2014
![Page 125: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/125.jpg)
HA-WBRT ‘How-To’ Guide
Gondi IJROBP 78, 2010
![Page 126: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/126.jpg)
HA-WBRT ‘How-To’ Guide
Gondi IJROBP 78, 2010
![Page 127: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/127.jpg)
NRG CC001 – WBRT + Memantine +/- Hippocampal Avoidance
• WBRT 30Gy + Memantine x 6 m
• HA-WBRT 30 Gy + Memantine x 6m
• Primary Objective:
• Determine if HA-WBRT increases time to neurocognitive decline on: HVLT-R, COWA, TMT A and B.
• Hypothesis: HA-WBRT will increase time to failure at 6 months from 53.8% to 64.8%
• 510 accrued over 63 months 382 evaluable pts
![Page 128: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/128.jpg)
Outline
• High Grade Gliomas
• Low Grade Gliomas
• Brain Metastases
• Benign/Misc.
![Page 129: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/129.jpg)
Pituitary Adenoma
![Page 130: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/130.jpg)
Pituitary Adenoma: Non-functioningConstants in XRT Literature
• No dose response above 45 Gy
(54 Gy for functioning adenomas)
• LC 90+% for non-functioning
• 1% vision toxicity
• 1% secondary malignancy
![Page 131: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/131.jpg)
Pituitary Adenomas:General Treatment Schema
• Observation
• Surgery 1st
– trans-sphenoidal resection usually
– Prolactinomas – often medications 1st
• If GTR: No RT
• If STR: Observe vs. RT– RT – if secretory
– RT – if ultimate growth would impact function (vision)
– RT – if ultimate growth would compromise treatment options (SRS now vs. EBRT later)
– Otherwise can observe a STR (i.e., salvage RT is same LC as immediate PORT)
![Page 132: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/132.jpg)
Pituitary Adenoma: Non-Functioning
![Page 133: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/133.jpg)
Meningiomas
![Page 134: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/134.jpg)
n = 265 pts1928-1954
GRADE DEFINITION OF EXTENT OF RESECTION 10 y LF
I Gross total resection of tumor, dural attachments and abnormal bone
10%
II Gross total resection of tumor, coagulation of dural attachments
20%
III Gross total resection of tumor without resection or coagulation of dural attachments, or extraduralextensions (e.g. invaded or hyperostotic bone)
30%
IV Partial resection of tumor 44%
V Simple decompression (biopsy) N/A
Meningioma: Simpson’s Grade
Simpson, J Neurol Neurosurg Psychiat 20, 1957
![Page 135: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/135.jpg)
RTOG 0539 – Phase II Meningioma
• Low Risk: Grade I: GTR (Simpson I-III)
STR (Simpson IV-V)
• Intermediate: Grade I: Recurrent
Grade II: GTR
• High Risk: Grade II: Recurrent
STR
Grade III: new, recurrent, GTR, STR
![Page 136: ASTRO Refresher Course Adult CNS Tumors Spring 2016 · 2016-03-01 · ASTRO Refresher Course –Adult CNS Tumors Spring 2016 Scott G. Soltys, M.D. Department of Radiation Oncology](https://reader034.fdocuments.us/reader034/viewer/2022052408/5f0d45657e708231d439848e/html5/thumbnails/136.jpg)
RTOG 0539 – Phase II Meningioma
• Low Risk: Observation
• Intermediate: 54 Gy to GTV + 1.0 cm CTV + 0.3-0.5 cm PTV
– CTV may be reduced to 0.5 cm at natural barriers
• High Risk: 60 Gy to GTV + 1.0 cm CTV
54 Gy to GTV + 2.0 cm CTV + 0.3-0.5 cm PTV
No edema or dural tail included in GTV
Critical Structure Group II Group IIILenses 5 Gy 7 GyRetinae 45 Gy 50 GyOptic Nerves 50 Gy 55 GyOptic Chiasm 54 Gy 56 GyBrainstem 55 Gy 60 Gy